ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024
ALGS stock results show that Aligos Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires.
Axsome Therapeutics, Q1
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report). The company’s shares closed yesterday at $20.34.
The company raised guidance for sales of its drug for relapsing multiple sclerosis.
- Clinical trial will evaluate CX-801 as monotherapy and in combination with KEYTRUDA in patients with advanced metastatic solid tumors including melanoma, renal cell carcinoma and head and neck ...
Summit's flagship drug candidate, Ivonescimab, shows promise in treating non-small cell lung cancer in Phase 3 trials. Read ...
SAN DIEGO (AP) — SAN DIEGO (AP) — Halozyme Therapeutics Inc. (HALO) on Tuesday reported first-quarter net income of $76.8 million. On a per-share basis, the San Diego-based company said it had ...
WARREN, N.J. (AP) — WARREN, N.J. (AP) — Aquestive Therapeutics Inc. (AQST) on Tuesday reported a first-quarter loss of $12.8 million, after reporting a profit in the same period a year earlier. The ...
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4 ...
Context Therapeutics is advancing its experimental therapy being developed to treat solid tumors in gynecologic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback